From the Guidelines
Fluorescence in situ hybridization (FISH) analysis in marginal zone lymphoma (MZL) is used to detect specific chromosomal abnormalities, with t(11;18) translocation being one of the notable abnormalities associated with this condition, particularly in gastric MALT lymphomas. The use of FISH in diagnosing MZL is highlighted in the context of evaluating the stomach for MZL, where it is mentioned as an optional test to detect t(11;18) translocation 1. This translocation is significant because it creates an API2-MALT1 fusion gene, which is associated with resistance to Helicobacter pylori eradication therapy. While other FISH abnormalities such as trisomy 3, trisomy 18, and deletions in 7q31 are commonly found in MZL, particularly in splenic and extranodal subtypes, the provided evidence does not specify these in the context of the question. However, it is essential to integrate FISH findings with clinical, morphological, and immunophenotypic findings for accurate diagnosis and treatment planning. Key points to consider in the use of FISH for MZL diagnosis include:
- The t(11;18) translocation is specifically mentioned in the context of gastric MALT lymphomas.
- FISH analysis is an optional tool in the diagnostic workup for MZL, particularly for detecting the t(11;18) translocation.
- The interpretation of FISH results should be integrated with other diagnostic findings for comprehensive patient evaluation. Given the information provided and focusing on the most recent and highest quality study, the primary FISH abnormality associated with Marginal Zone Lymphoma, as per the question's context, is the t(11;18) translocation, especially relevant in gastric MALT lymphomas 1.
From the Research
Fluorescence In Situ Hybridization (FISH) Abnormalities in Marginal Zone Lymphoma
There are no research papers provided to directly answer the question about the specific FISH abnormalities associated with Marginal Zone Lymphoma. The studies provided discuss the classification, clinical presentation, management, and treatment of Marginal Zone Lymphoma but do not mention FISH abnormalities specifically 2, 3, 4, 5, 6.
Key Points About Marginal Zone Lymphoma
- Marginal Zone Lymphoma (MZL) is an indolent B-cell lymphoma with three distinct subtypes: splenic marginal zone lymphoma (SMZL), nodal marginal zone lymphoma (NMZL), and extranodal mucosa-associated lymphoid tissue (MALT) lymphoma 2, 3, 5, 6.
- The subgroups of MZL share some common features but differ in biology and behavior 2, 3, 5.
- Treatment approaches vary and can include watchful waiting, surgery, localized radiation therapy, rituximab with chemotherapy, and newer therapies like bendamustine and phosphoinositide 3-kinase inhibitors 2, 4, 6.
- Recent studies highlight the potential of novel agents targeting the B-cell receptor signaling pathway, such as ibrutinib, in treating relapsed MZL 4.
- There is a need for more clinical trials to establish standard therapies and assess their impact on patient outcomes 6.